Caas Capital Management LP Eli Lilly & CO Put Options Transaction History

Caas Capital Management LP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2022 Feb 14, 2023	SELL	$321.55 - $374.67 $4.21 Million - $4.91 Million	-13,100 Reduced 59.28%	9,000 $3.29 Million
Q3 2022 Nov 14, 2022	BUY	$296.48 - $337.87 $3.88 Million - $4.43 Million	13,100 Added 145.56%	22,100 $7.15 Million
Q1 2022 May 13, 2022	SELL	$234.69 - $291.66 $1.17 Million - $1.46 Million	-5,000 Reduced 35.71%	9,000 $2.58 Million
Q2 2021 Aug 16, 2021	SELL	$180.55 - $233.54 $6.86 Million - $8.87 Million	-38,000 Reduced 73.08%	14,000 $3.21 Million
Q1 2021 May 17, 2021	SELL	$164.32 - $212.72 $4.6 Million - $5.96 Million	-28,000 Reduced 35.0%	52,000 $9.72 Million
Q4 2020 Feb 12, 2021	BUY	$130.46 - $172.63 $4.57 Million - $6.04 Million	35,000 Added 77.78%	80,000 $13.5 Million
Q3 2020 Nov 09, 2020	SELL	$146.22 - $169.13 $3.36 Million - $3.89 Million	-23,000 Reduced 33.82%	45,000 $6.66 Million
Q2 2020 Aug 14, 2020	BUY	$136.42 - $164.18 $3.14 Million - $3.78 Million	23,000 Added 51.11%	68,000 $11.2 Million
Q1 2020 May 15, 2020	BUY	$119.05 - $147.35 $5.36 Million - $6.63 Million	45,000 New	45,000 $6.24 Million

3,887

763M

6.34M

7.97M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $864B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Caas Capital Management LP with notifications on news.